Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years

Recommendations of the Advisory Committee on Immunization Practices--United States, 2022

Tara C. Anderson, DVM, PhD; Nina B. Masters, PhD; Angela Guo, MPH, MBA; Leah Shepersky, MPH; Andrew J. Leidner, PhD; Grace M. Lee, MD; Camille N. Kotton, MD; Kathleen L. Dooling, MD

Disclosures

Morbidity and Mortality Weekly Report. 2022;71(3):80-84. 

In This Article

Precautions

Moderate or Severe Acute Illness With or Without Fever

In general, vaccination should be delayed for patients experiencing moderate or severe acute illness.[17]

Current Episode of Herpes Zoster

RZV is not a treatment for herpes zoster or postherpetic neuralgia. If a person is experiencing an episode of herpes zoster, vaccination should be delayed until the acute stage of the illness is over and symptoms abate.[17]

processing....